That's right, three-quarters of a million dollars to save your kid's life, and that's just for the first year. Luckily, the price drops after that -- to a mere $375,000 a year for subsequent years... because anything more would just be a selfish form of price gouging.
The drug company argues the first year is so expensive because it requires six treatments, as if $125,000 per treatment is somehow justifiable. The medication was approved by the FDA in December, and praised by the Muscular Dystrophy Association and Cure SMA as the first and only approved treatment for SMA.
Lest you think the medication is just a tad overpriced, a spokesman for Biogen said the cost was "carefully considered" and "fairly in line with other therapies for rare orphan diseases," according to CBS News. Although the price could go down with insurance coverage, discounts, or rebates, it's still hardly in the realm of affordable.